Observational studies at the SCAI meeting favored the dual GIP/GLP-1 receptor agonist tirzepatide (Mounjaro, Zepbound) over ...

Vinay Prasad, MD, MPH, a frequent critic of the FDA and COVID-19 lockdowns and vaccination policies, will be the next ...

Overall, 72% of 36,949 infants were immunized in the 2023-2024 RSV season with either the bivalent RSV prefusion F protein ...

SAN DIEGO -- A new blood test can predict the development of metabolic dysfunction-associated steatotic liver disease (MASLD) ...

On a 5-point Likert scale, AI responses scored a 4.2 on both quality and empathy compared with scores of 3.0 on quality and 2 ...

Fremanezumab reduced migraine attacks and depression symptoms in migraine patients with major depressive disorder.

The studies were postmarketing requirements the FDA requested in 2013 of all companies with new opioid analgesics for chronic ...

Depressive symptoms rose progressively in the 15 years leading up to dementia diagnosis, with the highest elevations ...

The issue is that banning all PFAS from medical devices would threaten care for the Americans who receive 300,000 newly ...